Emerging immunotherapies for malignant glioma: From immunogenomics to cell therapy

Keyphrases

• Cell Therapy 100%
• Central Nervous System 50%
• Chimeric Antigen Receptor T-cell Therapy 50%
• FDA-approved Drugs 50%
• Glioblastoma 100%
• Immune Checkpoint Blockade 50%
• Immune Response 50%
• Immune-oncology 50%
• Immunogenomics 100%
• In Cancer 50%
• Malignant Glioma 100%
• Neoantigen Vaccine 50%
• Patient Demographics 50%
• Patient Selection 50%
• Treatment Timing 50%
• Vaccine Research 50%

Immunology and Microbiology

• Central Nervous System 33%
• Chimeric Antigen Receptor T-Cell Therapy 33%
• Immune Checkpoint Blockade 33%
• Immune Response 33%
• Immunity 66%
• Immunotherapy 100%
• Neoantigen 33%